Precigen, Inc. EV/Sales

EV/Sales of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.

Highlights and Quick Summary

Current EV/Sales of Precigen, Inc. is 18.42 (as of December 30, 2020)
  • EV/Sales for the quarter ending June 29, 2021 was 13.6 (a -5.74% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Sales increased by 100.09%
  • Annual EV/Sales for 2020 was 18.42 (a 69.16% increase from previous year)
  • Annual EV/Sales for 2019 was 10.89 (a 97.03% increase from previous year)
  • Annual EV/Sales for 2018 was 5.53 (a -21.42% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of Precigen, Inc.

Most recent EV/Salesof PGEN including historical data for past 10 years.

Interactive Chart of EV/Sales of Precigen, Inc.

Precigen, Inc. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 13.6 14.43
2020 18.42 6.8 9.78 6.29 18.42
2019 10.89 9.4 10.25 6.35 10.89
2018 5.53 11.08 8.68 8.8 5.53
2017 7.03 11.15 13.43 10.7 7.03
2016 14.09 16.53 13.86 20.24 14.09
2015 17.97 20.6 39.52 47.41 17.97
2014 36.49 36.34 70.43 84.31 36.49
2013 33.63 55.83 0.78 0.78 33.63
2012 0.78 0.78 0.78
2011 0.78

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.